Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil

Genetics and Molecular Research

Volumn 7, Issue 1, 2008, Pages 207-216

  Pinto, G R ^a,b   Yoshioka, F K N ^a   Silva, R L L ^b   Clara, C A ^c   Santos, M J ^c   Almeida, J R W ^c   Burbano, R R ^d   Rey, J A ^e   Casartelli, C ^b  

^a FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BARRETOS CANCER HOSPITAL   (Brazil)

^d FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Arg72Pro; Gliomas; Pro47Ser; Single nucleotide polymorphisms; TP53

Indexed keywords

ARGININE; PROLINE; SERINE;

ADULT; AGED; APOPTOSIS; ARTICLE; ASTROCYTOMA; BRAZIL; CANCER PATIENT; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL GROWTH; CODON; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPENDYMOMA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLIOMA; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR SUPPRESSOR GENE;

EID: 42149133853     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/vol7-1gmr415     Document Type: Article

References (41)

1. Beckman G, Birgander R, Sjalander A, Saha N, et al. (1994). Is p53 polymorphism maintained by natural selection? Hum. Hered. 44: 266-270.
2. Biros E, Kalina I, Kohut A, Bogyiova E, et al. (2002). Allelic and haplotype frequencies of the p53 polymorphisms in brain tumor patients. Physiol. Res. 51: 59-64.
3. Bonafe M, Barbi C, Storci G, Salvioli S, et al. (2002). What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. Exp. Gerontol. 37: 1263-1271.
4. Buyru N, Tigli H and Dalay N (2003). P53 codon 72 polymorphism in breast cancer. Oncol. Rep. 10: 711-714.
5. Dong M, Nio Y, Yamasawa K, Toga T, et al. (2003). p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J. Surg. Oncol. 82: 111-120.
6. Drummond SN, De Marco L, Pordeus IA, Barbosa AA, et al. (2002). TP53 codon 72 polymorphism in oral squamous cell carcinoma. Anticancer Res. 22: 3379-3381.
7. Dumont P, Leu JI, Della Pietra A III, George DL, et al. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33: 357-365.
8. Fan R, Wu MT, Miller D, Wain JC, et al. (2000). The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 9: 1037-1042.
9. Felley-Bosco E, Weston A, Cawley HM, Bennett WP, et al. (1993). Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am. J. Hum. Genet. 53: 752-759.
10. Granja F, Morari J, Morari EC, Correa LA, et al. (2004). Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett. 210: 151-157.
11. Hishida A, Matsuo K, Tajima K, Ogura M, et al. (2004). Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk. Lymphoma 45: 957-964.
12. Ignaszak-Szczepaniak M, Horst-Sikorska W, Sawicka J, Kaczmarek M, et al. (2006). The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients. Oncol. Rep. 16: 65-71.
13. Jin X, Wu X, Roth JA, Amos CI, et al. (1995). Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16: 2205-2208.
14. Jones JS, Chi X, Gu X, Lynch PM, et al. (2004). p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin. Cancer Res. 10: 5845-5849.
15. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, et al. (2007). Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet. Cytogenet. 173: 38-42.
16. Khayat AS, Lobo GL, Moura LE, de Assumpcao PP, et al. (2005). Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma. Clin. Exp. Med. 5: 161-168.
17. Kirk BW, Feinsod M, Favis R, Kliman RM, et al. (2002). Single nucleotide polymorphism seeking long term association with complex disease. Nucleic Acids Res. 30: 3295-3311.
18. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, et al. (2002). The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61: 215-225.
19. Lane DP (1992). Cancer. p53, guardian of the genome. Nature 358: 15-16.
20. Leu JI, Dumont P, Hafey M, Murphy ME, et al. (2004). Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6: 443-450.
21. Li X, Dumont P, Della PA, Shetler C, et al. (2005). The codon 47 polymorphism in p53 is functionally significant. J. Biol. Chem. 280: 24245-24251.
22. Ngan HY, Liu VW and Liu SS (1999). Risk of cervical cancer is not increased in Chinese carrying homozygous arginine at codon 72 of p53. Br. J. Cancer 80: 1828-1829.
23. Oren M (2003). Decision making by p53: life, death and cancer. Cell Death Differ. 10: 431-442.
24. Papadakis ED, Soulitzis N and Spandidos DA (2002). Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br. J. Cancer 87: 1013-1018.
25. Parhar P, Ezer R, Shao Y, Allen JC, et al. (2005). Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res. Mol. Brain Res. 137: 98-103.
26. Peixoto GD, Hsin LS, Snijders P, Wilmotte R, et al. (2001). Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. Cancer Lett. 162: 231-235.
27. Perrone F, Mariani L, Pastore E, Orsenigo M, et al. (2007). p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. Cancer 109: 2461-2465.
28. Qie M, Zhang Y and Wu J (2002). Study on the relationship between cervical cancer and p53 codon 72 polymorphism. HuaXi YiKe DaXue XueBao 33: 274-275.
29. Shen H, Zheng Y, Sturgis EM, Spitz MR, et al. (2002). P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 183: 123-130.
30. Sifuentes AA and Reyes RM (2003). Risk factors for cervico-uterine cancer associated to HPV: p53 codon 72 polymorphism in women attending hospital care. Ginecol. Obstet. Mex. 71: 12-15.
31. Soussi T and May P (1996). Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260: 623-637.
32. Toyama T, Zhang Z, Nishio M, Hamaguchi M, et al. (2007). Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 9: R34.
33. Tsai MH, Lin CD, Hsieh YY, Chang FC, et al. (2002). Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112: 116-119.
34. Uno M, Oba-Shinjo SM, Wakamatsu A, Huang N, et al. (2006). Association of TP53 mutation, p53 overexpression, and p53 codon 72 polymorphism with susceptibility to apoptosis in adult patients with diffuse astrocytomas. Int. J. Biol. Markers 21: 50-57.
35. Wang XW, Yeh H, Schaeffer L, Roy R, et al. (1995). p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet. 10: 188-195.
36. Weston A, Perrin LS, Forrester K, Hoover RN, et al. (1992). Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol. Biomarkers Prev. 1: 481-483.
37. Wu WJ, Kakehi Y, Habuchi T, Kinoshita H, et al. (1995). Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn. J. Cancer Res. 86: 730-736.
38. Xi YG, Ding KY, Su XL, Chen DF, et al. (2004). p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 25: 2201-2206.
39. Yu MW, Yang SY, Chiu YH, Chiang YC, et al. (1999). A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 29: 697-702.
40. Zehbe I, Voglino G, Delius H, Wilander E, et al. (1998). Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 352: 1441-1442.
41. Zhu ZZ, Wang AZ, Jia HR, Jin XX, et al. (2007). Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn. J. Clin. Oncol. 37: 385-390.